Today we announced our participation in the upcoming JMP Securities Hematology and Oncology Summit, where our CEO Troy Wilson, Ph.D., J.D. is scheduled to participate in a virtual fireside chat. Learn more and access the live webcast: https://lnkd.in/gm8hf6k2
Kura Oncology, Inc.
生物技术研究
San Diego，California 22,687 位关注者
Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.
关于我们
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.
- 网站
-
https://www.kuraoncology.com
Kura Oncology, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- San Diego，California
- 类型
- 上市公司
- 创立
- 2014
- 领域
- Oncology、Precision Medicine、Targeted Therapeutics、Biomarkers、Solid Tumors、Blood Cancers和Research and Development
地点
Kura Oncology, Inc.员工
动态
-
NEW DATA TO BE PRESENTED AT #ASH24! Don't miss updates from the KOMET-007 #clinicaltrial investigating the potential of #menin inhibitor combination therapy in patients with newly diagnosed and R/R #AML. Connect with us at Booth 2701 to learn more about the KOMET clinical trials program in AML. Explore our ongoing clinical trials: https://bit.ly/48ZF2cx
-
-
Today we announced a global strategic collaboration with Kyowa Kirin to develop and commercialize #ziftomenib, our selective oral menin inhibitor being investigated for the treatment of patients with acute myeloid leukemia (#AML) and other hematologic malignancies. This partnership represents a significant step forward in our mission to realize the promise of precision medicines for #cancer patients. Learn more about our joint effort: https://lnkd.in/g9RepAZw Kyowa Kirin, Inc.- U.S.
-
The latest research points to NPM1-m as a foundational driver mutation of ~30% of #AMLs and has been predominantly shown to be stable and persistent even after relapse. This makes knowing your patients' NPM1-m status essential in this complex disease. Understanding the challenges posed by NPM1-m is crucial for investigating additional treatment options. Explore our ongoing #clinicaltrials for NPM1-m AML:?https://bit.ly/4fM9ppe
-
-
We’re proud to debut “From Lab to Clinic: The Origin and Journey of Menin Inhibitors for AML Research,”?a documentary-style video spotlighting the long-term partnership that led to the development of our investigational menin inhibitor for the treatment of acute myeloid leukemia (AML).? ? From its inception, the heart of our menin inhibitor program has been collaboration. From Jolanta Grembecka, Ph.D., and Tomasz Cierpicki’s, Ph.D. breakthrough menin inhibitor research at the University of Michigan, to The Leukemia & Lymphoma Society’s Therapeutic Accelerator Program, to partnering with Kura Oncology for molecule optimization and clinical development, menin inhibitors are the outcome of multiple dedicated parties that hope to make a difference in the lives of cancer patients.?? ? View the full video to learn our menin inhibitor’s origin story and our hope for its future: https://lnkd.in/drnAJcF7 ? #AML #MeninInhibitors #FromLabToClinic
-
Are you a passionate and motivated individual interested in creating meaningful change in the #cancer space? Consider joining #TeamKura!? ????? Our award-winning team is made up of science-driven creative innovators who help advance our precision medicines pipeline of potential life-changing therapies for cancer patients. We strive to bring out the best in each other while always staying focused on delivering with excellence.???? ????? If our values resonate with you, check out our open positions and apply to join our team today: https://bit.ly/3U9bmnR? #Hiring #LifeAtKura????
-
We are honored to have once again participated in this year’s annual #LightTheNight San Diego event for the fourth year in a row, and we extend our heartfelt thank you to both #TeamKura and the The Leukemia & Lymphoma Society for your unwavering commitment in the fight against blood cancers.?? ? Your dedication and support embody our shared mission of advancing research and advocacy for cancer patients everywhere. Let’s continue to light the way toward better blood cancer treatments!??? ? Check out our Kura sponsored photo booth and pictures of the event:?? ? #LightTheNightSanDiego #FightBloodCancer?
-
-
At Kura, we are committed to inspiring the next generation of scientists and innovators. Today, on #NationalSTEMDay, we celebrate the power of #STEM education and its impact on the future.?? ? This year, we partnered with Life Science Cares San Diego and MANA de San Diego to provide educational resources and hands-on learning activities for students at the Science, Technology, Engineering, Arts, and Math (STEAM) volunteer event on #PiDay.?? ? Our mentorship initiatives for underserved communities aim to empower young minds in STEM. Together, we can shape a brighter future through science and education!
-
-
Today we announced our Q3 2024 #earnings, detailing updates on business and pipeline milestones as we approach #ASH24 and the end of the year.?? ? View the full release: https://bit.ly/40CyfDt ? Tune in to our investor webcast call today at 4:30 p.m. ET:?https://lnkd.in/gEMU23fE ?
-
November is #NationalFamilyCaregiversMonth, a time to recognize and honor the dedication of countless caregivers who provide support to their loved ones with #cancer. Their care and compassion are a lifeline for millions of people in the United States. Kura Oncology is committed to empowering caregivers and has resources to help them stay?informed about cancer and connect them with others in the blood cancer community. Learn more: https://bit.ly/3C4uf4t
-